-The Business Standard CAG says GSPL did not safeguard its own Interest leading to passing on of undue benefit of Rs 52 cr to RIL In what could add more teeth to the opposition party's allegations against the Narendra Modi-led Gujarat government, the Comptroller and Auditor General of India (CAG)'s latest report has brought out fresh details of undue favour by state public sector undertakings (PSUs) to Reliance Industries Limited (RIL) and...
More »SEARCH RESULT
Total Matching Records found : 6904
When innovation is under threat-Swati Piramal
-The Financial Express A patent law that is transparent, based on principles of good science & encourages innovation is in India's Interest In 500 BC, in the Greek city of Sybaris, it was proclaimed that "encouragement was held out to all who should discover any new refinement in luxury, the profits arising from which were secured to the inventor by patent for the space of a year." England followed with the Statute...
More »Gujarat Bill ending role of Governor, CJ to choose ombudsman passed-Darshan Desai
-The Hindu Amid protests and a walkout by Opposition MLAs in the Assembly, the ruling Bharatiya Janata Party on Tuesday pushed through a new Gujarat Lokayukta Aayog Bill, 2013 that ostensibly seeks to end the role of the Governor and the Chief Justice of the High Court in appointing the ombudsman. The Bill proposes a seven-member selection panel headed by the Chief Minister, which will recommend a candidate for the Lokayukta's post...
More »Glivec lesson for pharma: Patented drugs must be priced smartly-Kiran Mazumdar Shaw
-The Economic Times To ensure access to healthcare for all, India must harness innovation in discovering drugs, in developing therapeutics and in delivering affordable healthcare. It is in the light of these facts that one should evaluate the impact of the Indian Supreme Court's ruling in the case involving patent protection for Novartis AG's cancer drug, Glivec. Glivec was the first-of-its-kind cancer drug for leukaemia patients with patent protection in nearly 40...
More »Rx: Make All Clinical Trial Data Public
-The Economic Times Should drug companies make clinical trials data public? All over the world, drug regulators are increasingly in favour of doing so, much to the discomfort of pharmaceutical companies, and the London-based European Medicines Agency (EMA) is the first mover in this regard. As the journal Nature reports, EMA is likely to do so by next year, at least for some clinical trials data. On April 19, all the...
More »
